Shangjian Bio

Shangjian Bio is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative antibody therapeutics. The company focuses on oncology and autoimmune diseases, leveraging its proprietary technology platforms, such as the B-Body bispecific platform, to develop a diverse pipeline of monoclonal and bispecific antibodies. Its lead programs include SG001, a PD-1 inhibitor in Phase 2 clinical trials, and several first-in-class or best-in-class candidates targeting TGF-beta/PD-L1 and CD38. Shangjian Bio maintains integrated capabilities spanning from early-stage discovery to pilot-scale GMP manufacturing. Supported by prominent investors like Legend Capital and CICC Capital, the company aims to address significant unmet medical needs through precision biologics.